A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.
Vassilis GoulasAlexandra Kouraklis-SymeonidisKyriaki ManousouVassileios LazarisGeorge PairasParaskevi KatsaouniEugenia VerigouVassiliki LabropoulouVassiliki PesliPanagiotis KaiafasUrania PapageorgiouArgiris SymeonidisPublished in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2020)
TDT patients prefer to receive oral ICT and are more satisfied of the burden of deferasirox-containing ICT, even though those receiving parenteral ICT are more satisfied by the effectiveness of their treatment. No differences in HRQoL were not noted between patients receiving parenteral versus oral ICT.